Kitov Pharma Cash Flow - Annual (NASDAQ:KTOV)

Add to My Stocks
$1.72 $0.03 (1.71%) KTOV stock closing price Sep 21, 2018 (Closing)

The Kitov Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. While its important to look at the Kitov Pharma debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Kitov Pharma revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Kitov Pharma cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Kitov Pharma had cash and cash equivalents of $6.75M at the beginning of the year and $3.94M at year end for 2017. The cash from operating activities for Kitov Pharma is $ 2017, which saw a decrease from previous year.

View details of Kitov Pharma cash flows for latest & last 10 financial years
show more
Fiscal year is Jan - Dec20172016201520142013
Net Income Cash Flow
-13M-12.12M-4.2M-5.25M-2.62M
Depreciation Depletion Amortization Cash-Flow-----
Net Increase (Decrease) in Assets Liabilities----0.13M-
Cash From (used in) Discontinued Operations-----
Other Adjustments Net4.25M5.59M--1.98M
Net Cash from (used by) Operating Activities
-8.62M-6.26M-3.3M-4.52M-0.51M
Increase (Decrease) in Prop Plant And Equipment-0.01M-0.01M-0.01M--
Acquisition Disposition of Subsidiaires-1.73M----
Increase (Decrease) in Investments4.41M-7.89M---
Other Cash Inflow (Outflow) from Investment Activities-----
Net Cash from (used by) Investment Activities
2.77M-7.9M-0.01M--
Issuance (Purchase) of Equity Shares3.52M12.32M15.13M7.25M-
Issuance (Repayment) of Debt Securities-0.13M-0.01M-0.29M-0.73M-
Increase (Decrease) in Bank & Other Borrowings-0.01M----
Payment of Dividends & Other Cash Distributions-----
Other Cash from (used by) Financing Activities-0.38M-1.89M-2.21M-0.69M-0.01M
Net Cash from (used by) Financing Activities
2.99M10.42M12.63M5.82M-
Effect of Exchange Rate Changes on Cash--0.05M-0.07M-0.17M-
Net Change in Cash & Cash Equivalents
-2.81M-3.8M9.24M1.12M-
Cash & Equivalents at Beginning of Year6.75M10.55M1.31M--
Cash & Equivalents at Year End3.94M6.75M10.55M1.31M-
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Kamada financial analysis

Kitov Pharma stock comparison chart provides an easy way to compare the stock price with peers along with details of Kitov Pharma stock price history.
The statement of cash flows can be categorized into three main sections:

  • Kitov Pharma saw a positive change in Net Change in Cash and Cash Equivalents of $-2.81M in 2017. Apart from the Kitov Pharma stock price, this is one of the things an investor looks for, as it shows the net change in cash on hand for a company, compared to previous period.
  • Cash Flow from operating activities: Kitov Pharma reported a negative operating cash flow of $-8.62M for 2017 and has seen a decrease from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: Kitov Pharma generated $2.77M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Kitov Pharma earned $2.99M from financing activities, in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Kitov Pharma Cash Flow

Annual Cash Flow Statements For Kitov Pharmaceuticals Holdings Ltd (ADR) Peers

Compugen cash flow, IsoRay cash flow, Kamada cash flow, RENEURON GP PLC cash flow, XTL Biopharma cash flow